Roberto Ferrara, Medical Oncology Researcher at Vita-Salute San Raffaele University, shared a post on X:
“Blocking PD-1 and PD-L1 at the same time has strong biological rationale because with an anti-PD1 alone, PD-L1 continues to inhibit B7.1 (the 2nd immuno signal). But data with PD-1/PD-L1 bispecific not so clinically encouraging.
Food for thoughts from Benjamin Besse.”
Other articles about PD-1/PD-L1 on OncoDaily.
